公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2019 | Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma | LI-CHUN LU ; CHIUN HSU ; YU-YUN SHAO ; Chao Y.; Yen C.-J.; I-LUN SHIH ; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen ; JHE-CYUAN GUO ; TSUNG-HAO LIU ; CHIH-HUNG HSU ; ANN-LII CHENG | Liver Cancer | 46 | 44 | |
2012 | Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma | YU-YUN SHAO ; Chen C.-L.; MING-CHIH HO ; Huang C.-C.; Tu H.-C.; CHIH-HUNG HSU ; ANN-LII CHENG | Anticancer Research | 9 | 10 | |
2017 | Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer | YI-HSIN LIANG ; Wei, C. H.; Hsu, W. H.; YU-YUN SHAO ; Lin, Y. C.; Chou, P. C.; ANN-LII CHENG ; KUN-HUEI YEH | Support Care Cancer | 10 | 10 | |
2021 | Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma | BANG-BIN CHEN ; YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH | Diagnostics (Basel, Switzerland) | 7 | 7 | |
2010 | Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Cancer | 141 | 148 | |
2019 | Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma | YU-YUN SHAO ; TSUNG-HAO LIU ; CHIUN HSU ; LI-CHUN LU ; YING-CHUN SHEN ; ZHONG-ZHE LIN ; ANN-LII CHENG ; CHIH-HUNG HSU | Liver International | 56 | 58 | |
2021 | Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials | BANG-BIN CHEN ; ZHONG-ZHE LIN ; YU-YUN SHAO ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH | Cancers | 4 | 3 | |
2012 | Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Lee, Kuan-Der; Hsiao, Chi-Huang; YEN-SHEN LU ; Huang, Chien-Chung; YING-CHUN SHEN ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 26 | 25 | |
2021 | Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma | YU-YUN SHAO ; Sun, Nai-Yun; YUNG-MING JENG ; YAO-MING WU ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu, Hey-Chi; ANN-LII CHENG ; ZHONG-ZHE LIN | Cells | 3 | 2 | |
2022 | Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study | Chen, Ching-Tso; CHIH-HUNG HSU ; ANN-LII CHENG ; YU-YUN SHAO | Anticancer research | 0 | 0 | |
2012 | Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy | ZHONG-ZHE LIN ; CHIUN HSU ; Hu F.-C.; YU-YUN SHAO ; DWANG-YING CHANG ; CHIH-HSIN YANG ; RUEY-LONG HONG ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncologist | 8 | 10 | |
2008 | Fatal thrombocytopenia after oxaliplatin-based chemotherapy | YU-YUN SHAO ; RUEY-LONG HONG | Anticancer Research | 19 | 20 | |
2009 | Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment | YU-YUN SHAO ; ZHONG-ZHE LIN ; PO-CHIN LIANG ; YU-WEN TIEN ; ANN-LII CHENG | Anticancer Research | 1 | 1 | |
2010 | Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. | YU-YUN SHAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Discovery medicine | 13 | 12 | |
2013 | The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; Chang Y.-L.; Huang C.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology (Switzerland) | 5 | 5 | |
2010 | Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma | YU-YUN SHAO ; Huang C.; PO-CHIN LIANG ; ZHONG-ZHE LIN | Asia-Pacific Journal of Clinical Oncology | 28 | 29 | |
2017 | Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells | YU-YUN SHAO ; MIN-SHU HSIEH ; Wang, Han Yu; Li, Yong Shi; Lin, Hang; Hsu, Hung Wei; Huang, Chung Yi; CHIH-HUNG HSU ; ANN-LII CHENG | Oncotarget | 12 | 9 | |
2011 | High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy | YU-YUN SHAO ; ZHONG-ZHE LIN ; Chen T.-J.; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 17 | 17 | |
2017 | High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; Lin H.; Li Y.-S.; Lee Y.-H.; Chen H.-M.; ANN-LII CHENG ; CHIH-HUNG HSU | Japanese Journal of Clinical Oncology | 34 | 31 | |
2015 | High serum transforming growth factor-β1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib | Lin T.-H.; YU-YUN SHAO ; Chan S.-Y.; Huang C.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG | Clinical Cancer Research | 78 | 78 | |